Draxxin (tulathromycin) is now registered for control of swine respiratory disease (SRD) in groups of pigs where SRD has been diagnosed.

Draxxin is the first and only injectable antibiotic with a control claim for use in pigs assessed to be at risk of developing SRD because of their proximity to sick animals.

With the additional label claim, Draxxin is indicated for the treatment of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida and Mycoplasma hyopneumoniae and for the control of SRD caused by Actinobacillus pleuropneumoniae, Pasteurella multocida and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.

“This new claim provides Canadian veterinarians with an approved option for the use of Draxxin to control SRD in pigs where disease is expected,” says Don McDermid, DVM, veterinary operations for Pfizer Animal Health.

Egg Economics Supported

Université Laval and the Egg Farmers of Canada have established the country’s first Economic Research Chair on the Egg Industry.

Maurice Doyon, professor at the faculty of agriculture and food sciences and holder of this new chair, and his colleagues will be interested in issues such as the economic impact of disease control, concerns about the pricing model, international agreements on trade, and the costs and benefits associated with reducing the industry’s eco-footprint. They will also study changes in egg consumption habits, the rapid growth of the specialty egg market, growing consumer interest in the functional properties of these foods, and the impact of animal welfare on product demand.

Egg Farmers of Canada is contributing $700,000 to the chair over seven years.